Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

38 results about "MCH receptors" patented technology

New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture

The present invention relates to carboxamide compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R<1>, R<2>, R<3 >and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and / or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
Owner:BOEHRINGER INGELHEIM INT GMBH

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and / or eating disorders, particularly obesity and diabetes.
Owner:BOEHRINGER INGELHEIM INT GMBH

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

ActiveUS20040209865A1Influence the eating behaviour of mammalsLose weightBiocideOrganic chemistryCombinatorial chemistryObesity
The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R<1 >and R<2 >have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and / or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
Owner:BOEHRINGER INGELHEIM PHARM KG

MCH receptor antagonists

The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar1, Ar2, Ar3, L1, L2 and Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and Related Diseases
Owner:ELI LILLY & CO

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and / or eating disorders, particularly obesity and diabetes.
Owner:BOEHRINGER INGELHEIM INT GMBH

Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds

ActiveUS20040152742A1Influence the eating behaviour of mammalsLose weightBiocideOrganic chemistryObesityMedicinal chemistry
The present invention relates to amide compounds of general formula I wherein the groups and residues A, B, b, W, X, Y, Z, R<1>, R<2 >and R<3 >have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and / or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
Owner:BOEHRINGER INGELHELM PHARMA GMBH & CO KG

Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds

The present invention relates to amide compounds of general formula Iwherein the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and / or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
Owner:BOEHRINGER INGELHELM PHARMA GMBH & CO KG

Novel mch receptor antagonists

InactiveUS20070135485A1Treating ameliorating effectGood blood pressureBiocideOrganic chemistryDiabetes mellitusObesity
The present invention relates to a melanin concentrating hormone antagonist compound of formula I: or a pharmaceutically acceptable salt thereof, useful for the treamtment useful fog treating Type H diabetes and / or obesity.
Owner:ELI LILLY & CO

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and / or eating disorders, particularly obesity and diabetes.
Owner:BOEHRINGER INGELHEIM INT GMBH

Novel mch receptor antagonists

The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar1, Ar2, Ar3, L1, L2 and Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and Related Diseases.
Owner:ELI LILLY & CO

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula Iwherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and / or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
Owner:BOEHRINGER INGELHEIM PHARM KG

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and / or eating disorders, particularly obesity and diabetes.
Owner:BOEHRINGER INGELHEIM INT GMBH

Novel mch receptor antagonists

InactiveUS20090170913A1Control dietary habitMinimize preponderanceBiocideOrganic active ingredientsDiseaseNK1 receptor antagonist
The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar1, L1, R1, q, X, R2, R3, R4, and R5 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
Owner:ELI LILLY & CO

Pyrimidine derivatives and methods of treatment related to the use thereof

InactiveUS20090036448A1Reduces food intakeInduce satietyBiocideOrganic active ingredientsSubstance abuserBinge-eating disorder
The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.
Owner:TAISHO PHARMACEUTICAL CO LTD +1

Mch receptor antagonists

The present invention relates to novel compounds of the formula (I) which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression.
Owner:TAISHO PHARMACEUTICAL CO LTD

Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor

InactiveUS20080090863A1Reduces food intakeInduce satietyBiocideNervous disorderSubstance abuserBinge-eating disorder
The present invention encompasses novel substituted pyridine compounds of Formula (I): which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.
Owner:TAISHO PHARMACEUTICAL CO LTD +1

Thiazolopyridinone derivates as mch receptor antagonists

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein w, R1, q, p, R2, t, Ar1, L1, R3 and R4 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
Owner:ELI LILLY & CO

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and / or eating disorders, particularly obesity and diabetes.
Owner:BOEHRINGER INGELHEIM INT GMBH

β-ketoamide compounds with MCH antagonistic activity

InactiveUS7605176B2High affinityHigh to very high selectivityBiocideOrganic chemistryBeta-ketoamideObesity
Compounds of formula Iwherein the groups and residues A, B, b, X, Y, Z, R1, R2, R3, R5a and R5b have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and / or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.
Owner:BOEHRINGER INGELHEIM INT GMBH

1-naphthyl alkylpiperidine derivative

Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I)or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.
Owner:TAISHO PHARMACEUTICAL CO LTD

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

InactiveUS20050239826A1High affinityHigh to very high selectivityBiocideOrganic chemistryDiabetes mellitusMedicine
The present invention relates to alkyne compounds of general formula I wherein the groups and radicals A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one alkyne according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and / or eating disorders, particularly obesity and diabetes.
Owner:BOEHRINGER INGELHEIM INT GMBH

Novel MCH receptor antagonists

The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar<1>, Ar<2>, Ar<3>, L<1>, L<2> and Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and Related Diseases.
Owner:ELI LILLY & CO

Method for screening MCH receptor antagonist/agonist

The present invention relates to a screening method for a compound or a salt thereof that alters the binding property of MCH or a salt thereof to SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof, characterized by using MCH, a derivative or a salt thereof and SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof. The screening method of the present invention is useful for screening an SLT agonist, which can be used as an agent for promoting appetite (eating), and an SLT antagonist, which can be used as a prophylactic and / or therapeutic agent for obesity.
Owner:TAKEDA PHARMA CO LTD

7-piperidinoalkyl-3, 4-dihydroquinolone derivative

Problem To provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action.Solution A compound, a pharmaceutically acceptable salt or a hydrate thereof represented by the formula (I).
Owner:TAISHO PHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products